Home Healthcare Pharmaceuticals Molluscum Contagiosum Market

Molluscum Contagiosum Market Size, Share & Trends Analysis Report By Therapy (Cryotherapy, Curettage, Immune-modulating therapies, Topical therapies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:

Molluscum Contagiosum Market Size

The global molluscum contagiosum market size was valued at USD 2.53 billion in 2025 and is projected to grow from USD 2.65 billion in 2026 to USD 3.84 billion by 2034, registering a CAGR of 4.75% during the forecast period from 2026 to 2034. North America dominated the molluscum contagiosum market with a market share of 41.6% in 2025.

In recent years, there has been a surging prevalence and incidence of molluscum contagiosum worldwide, fostering the global molluscum contagiosum market expansion. Moreover, continual research and development activities leading to the development of new treatments that are more effective, safe, and convenient for patients are estimated to create opportunities for market growth.

Molluscum contagiosum is a common viral skin infection caused by the poxvirus. It manifests as small, raised, flesh-colored, or pink bumps on the skin with a central indentation. These bumps often appear in clusters and can be itchy, sore, or tender. Molluscum contagiosum is very contagious and can spread through direct skin-to-skin contact and contaminated objects like towels or clothing.

It commonly affects children, sexually active adults, and individuals with weakened immune systems. The infection typically resolves on its own within months to a few years without treatment. Still, medical intervention may be necessary to prevent its spread, alleviate symptoms, or address cosmetic concerns. Treatments include topical medications, cryotherapy (freezing), or minor surgical procedures to remove the lesions. It's important to avoid scratching or picking at the bumps to prevent further spread and secondary bacterial infections.

Top 2 Key Highlights

  • Topical therapy dominates the therapy segment
  • North America is the highest shareholder in the global market
Molluscum Contagiosum Market Size

Download a Free Sample To learn more about this report.

Therapy Insights

The market is bifurcated into cryotherapy, curettage, immune-modulating therapies, topical therapies, and others. The topical therapy segment is estimated to dominate the global market. Topical therapy for molluscum contagiosum, a viral skin infection, targets the lesions while minimizing systemic side effects directly. Various agents, such as cantharidin, podophyllotoxin, salicylic acid, tretinoin, and imiquimod, may be used. Cantharidin is a common choice, applied directly to the lesions in a clinical setting, causing blistering and subsequent lesion removal. Podophyllotoxin, salicylic acid, and tretinoin are often applied at home, targeting the lesions' growth mechanisms or promoting their shedding.

Moreover, Imiquimod boosts the immune response locally, aiding in lesion clearance. These treatments typically require consistent application over several weeks to months, with regular monitoring for adverse effects and lesion response. While topical therapy is generally safe and non-invasive, it may cause local irritation or skin reactions. Its efficacy varies among individuals and lesion types, and it may not be suitable for extensive or immunocompromised cases. Close supervision by a healthcare provider is essential for optimal outcomes.

Cryotherapy is a commonly used treatment for molluscum contagiosum, a viral skin infection caused by the molluscum contagiosum virus (MCV). In this procedure, liquid nitrogen or another cryogen is applied directly to the molluscum lesions, causing freezing and destruction of the infected tissue. This method works by inducing necrosis of the infected cells, leading to the eventual sloughing off of the lesions. Cryotherapy effectively treats individual lesions and can be particularly useful when dealing with numerous or widespread outbreaks.

Molluscum Contagiosum Market Size By Segments

Request Customizationto receive a tailored report.

Moreover, the treatment is quick and minimally invasive, typically causing mild discomfort and temporary skin irritation. However, multiple treatment sessions may be required for complete resolution, and there's a risk of scarring or pigment changes in some cases. Thus, cryotherapy offers a convenient and effective option for managing molluscum contagiosum, especially in cases where other treatments have proven ineffective or impractical. Nevertheless, its success may vary depending on the individual's immune response and the extent of the infection.

Curettage, a technique involving scraping or scooping out tissue, is occasionally used to treat molluscum contagiosum, a viral skin infection. Typically, curettage is employed when other treatment methods like topical medications or cryotherapy have failed or are unsuitable for the patient. During curettage, a healthcare professional uses a small, spoon-shaped instrument known as a curette to remove the raised, dome-shaped lesions caused by molluscum contagiosum from the skin surface.

Moreover, the procedure is usually performed under local anesthesia to minimize discomfort. Curettage physically removes the infected tissue, which can help accelerate the healing process by eliminating the source of the infection. However, there are risks associated with curettage, including scarring and potential recurrence of the lesions. Therefore, it's crucial for healthcare providers to carefully consider the appropriateness of curettage and discuss the potential benefits and risks with patients before proceeding with the procedure.

Molluscum Contagiosum Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global molluscum contagiosum market shareholder and is expected to expand substantially during the forecast period. The increasing prevalence of Molluscum Contagiosum among children and adults is propelling market growth in North America. Molluscum is a prevalent and contagious skin illness caused by the molluscipoxvirus. It affects almost six million individuals in the United States every year, with the highest occurrence observed in children between the ages of one and 14. The availability of cutting-edge medical facilities and hefty healthcare costs also fuel the need for efficient therapies. For instance, as per the Centers for Medicare & Medicaid Services, in 2022, healthcare spending in the United States increased by 4.1 percent, reaching a total of USD 4.5 trillion, which equates to USD 13,493 per person. Health spending constituted 17.3 percent of the nation's Gross Domestic Product.

Furthermore, there has also been a rise in the approval of novel treatment options by the regulatory authorities. For instance, in July 2023, Ycanth (cantharidin) was given approval by the FDA for the treatment of molluscum contagiosum in both adult and pediatric patients aged two and above. This therapy is provided in the office and applied topically. Ycanth (formerly known as VP-102) is the inaugural FDA-approved remedy for molluscum, a highly transmissible viral skin illness. Verrica Pharmaceuticals created it. Thus, the factors above augment the regional market expansion.

North America Molluscum Contagiosum Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Molluscum Contagiosum Market Trends

Asia-Pacific witnesses a rising incidence of MC due to population density and changing lifestyles. Increased healthcare awareness and adoption of advanced therapies present growth opportunities in this region. Furthermore, there has also been a rise in the clinical trials conducted to develop novel treatment options for molluscum contagiosum.

For instance, in December 2023, Verrica Pharmaceuticals Inc., a company specializing in dermatology therapeutics for skin diseases that require medical interventions, announced that its partner, Torii Pharmaceutical Co., Ltd., has released favorable results from a Phase 3 trial of TO-208 (also known as VP-102 and marketed as YCANTH™ in the U.S.) for the treatment of Molluscum Contagiosum ("molluscum") in Japan. The Phase 3 trial's top-line results indicate that many participants achieved complete clearance of all treated molluscum lesions at the end of the confirmatory study, which was the major measure of effectiveness. This outcome was statistically significant compared to the placebo. TO-208 exhibited good tolerability throughout the research. Consequently, these factors boost the regional market growth.

List of Key and Emerging Players in Molluscum Contagiosum Market

Verrica Pharmaceuticals
Novan Inc.
Veloce BioPharma LLC
Gurina Foundation

Key Industry Developments

April 2026
Ligand Pharmaceuticals strengthened its dermatology collaborations by expanding support for cantharidin-based therapies targeting molluscum contagiosum through strategic licensing and development initiatives.
February 2026
Novan, Inc. advanced research efforts focused on nitric oxide-based topical therapies for viral skin conditions, including molluscum contagiosum, supporting innovation in non-invasive dermatological treatments.
September 2025
Verrica Pharmaceuticals expanded the commercial availability of YCANTH® through broader market access initiatives and healthcare provider engagement programs, improving patient access to FDA-approved treatment options for molluscum contagiosum.
May 2025
Bausch Health strengthened its dermatology portfolio by expanding topical treatment offerings and educational initiatives supporting the management of viral skin infections, including molluscum contagiosum.

Report Scope

Segmentation

By Therapy 5
  • Cryotherapy
  • Curettage
  • Immune-modulating therapies
  • Topical therapies
  • Others

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Verrica Pharmaceuticals · Novan Inc. · Veloce BioPharma LLC · Gurina Foundation
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The molluscum contagiosum market size is valued at USD 2.65 Billion in 2026 and is projected to reach USD 3.84 Billion by 2034, at a CAGR of 4.75% during the forecast period 2026-2034.
North America dominated the market with a share of 41.6% in 2025.
The leading players in this market are Verrica Pharmaceuticals, Novan Inc., Veloce BioPharma LLC, Gurina Foundation.
The molluscum contagiosum market is projected to grow at a CAGR of 4.75% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now